WEBULL
WebtradeDownload

Keros Therapeutics Drops To US$10.66, Yet Insiders May Have Sold Too Early

Simply Wall St · 3d ago

Keros Therapeutics, Inc.'s (NASDAQ:KROS) value has fallen 11% in the last week, but insiders who sold US$484k worth of stock over the last year have had less success. Insiders would probably have been better off holding on to their shares given that the average selling price of US$13.86 is still lower than the current share price.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Keros Therapeutics Insider Transactions Over The Last Year

The President, Jasbir Seehra, made the biggest insider sale in the last 12 months. That single transaction was for US$113k worth of shares at a price of US$16.17 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$10.66. So it may not shed much light on insider confidence at current levels.

All up, insiders sold more shares in Keros Therapeutics than they bought, over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

Check out our latest analysis for Keros Therapeutics

insider-trading-volume
NasdaqGM:KROS Insider Trading Volume October 17th 2026

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Insiders At Keros Therapeutics Have Sold Stock Recently

Over the last three months, we've seen significant insider selling at Keros Therapeutics. In total, insiders sold US$95k worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.

Does Keros Therapeutics Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Keros Therapeutics insiders own 3.3% of the company, worth about US$7.2m. Whilst better than nothing, we're not overly impressed by these holdings.

So What Does This Data Suggest About Keros Therapeutics Insiders?

Insiders sold stock recently, but they haven't been buying. Despite some insider buying, the longer term picture doesn't make us feel much more positive. When you combine this with the relatively low insider ownership, we are very cautious about the stock. So we're not rushing to buy, to say the least. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we've found that Keros Therapeutics has 3 warning signs (1 doesn't sit too well with us!) that deserve your attention before going any further with your analysis.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.